 Andrew Kent
Concepts (41)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 6 | 2023 | 534 | 2.380 |
Why?
| | Hematologic Neoplasms | 2 | 2023 | 137 | 1.510 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 56 | 0.800 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1736 | 0.690 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 256 | 0.670 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 520 | 0.590 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2021 | 615 | 0.570 |
Why?
| | Genetic Variation | 1 | 2021 | 870 | 0.530 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 858 | 0.490 |
Why?
| | Stem Cell Transplantation | 2 | 2023 | 149 | 0.360 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 183 | 0.350 |
Why?
| | Signal Transduction | 1 | 2021 | 4509 | 0.310 |
Why?
| | Neoplasms | 1 | 2021 | 2097 | 0.290 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2023 | 172 | 0.290 |
Why?
| | Gamma Rays | 1 | 2023 | 48 | 0.220 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 56 | 0.210 |
Why?
| | Sulfonamides | 2 | 2023 | 445 | 0.210 |
Why?
| | Azacitidine | 1 | 2023 | 129 | 0.200 |
Why?
| | CD3 Complex | 1 | 2021 | 92 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2021 | 80 | 0.180 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 430 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 129 | 0.180 |
Why?
| | Recurrence | 1 | 2023 | 935 | 0.170 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 502 | 0.170 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 140 | 0.170 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 82 | 0.170 |
Why?
| | Benzimidazoles | 1 | 2020 | 138 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.160 |
Why?
| | T-Lymphocyte Subsets | 1 | 2021 | 383 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1355 | 0.150 |
Why?
| | Immunotherapy | 1 | 2021 | 474 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 695 | 0.140 |
Why?
| | Protein Binding | 1 | 2021 | 1889 | 0.130 |
Why?
| | Humans | 7 | 2023 | 114623 | 0.120 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3344 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2023 | 12542 | 0.080 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 104 | 0.050 |
Why?
| | Animals | 1 | 2021 | 31694 | 0.040 |
Why?
| | Aged | 1 | 2022 | 19061 | 0.010 |
Why?
|
|
Kent's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|